Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration

NCT00967213 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: ranibizumab

Sponsor

Novartis Korea Ltd.